Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lifecore Biomedical's Debt-to-Equity or its related term are showing as below:
LFCR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -34.76 Med: 0.79 Max: 97.92
Current: -5.23
During the past 13 years, the highest Debt-to-Equity Ratio of Lifecore Biomedical was 97.92. The lowest was -34.76. And the median was 0.79.
LFCR's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27
vs LFCR: -5.23
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lifecore Biomedical Debt-to-Equity Related Terms
Lifecore Biomedical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFCR vs DERM, ADCT, ANIK: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a Debt-to-Equity of -5.23 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #999999 out of 814 companies in the Drug Manufacturers industry.
Is Lifecore Biomedical's Debt-to-Equity too high?
Lifecore Biomedical's current Debt-to-Equity is -5.23. Based on the distribution chart, Lifecore Biomedical ranks #999999 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Debt-to-Equity compare to DERM and ADCT?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #999999 out of 814 companies for Debt-to-Equity. This places Lifecore Biomedical in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Debt-to-Equity is -5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.45, compared to a current price of $4.33 — trading 32.9% below its estimated fair value. The current Debt-to-Equity is -5.23. Lifecore Biomedical's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Debt-to-Equity is -5.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.33 is trading 32.9% below its estimated GF Value™ of $6.45.
GuruFocus considers Lifecore Biomedical to be Possible Value Trap.
Key valuation signals for LFCR:
Debt-to-Equity: -5.23
GF Value™: $6.45 vs. price of $4.33 (32.9% below fair value)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
51GF Score
Get the complete analysis for LFCR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
